Advances in the Study of Invasive Non-mucinous Adenocarcinoma
with Different Pathological Subtypes.
10.3779/j.issn.1009-3419.2022.102.51
- Author:
Ruke TANG
1
;
Lina BI
2
;
Bingquan XIANG
3
;
Lianhua YE
1
;
Ying CHEN
1
;
Guangjian LI
1
;
Guangqiang ZHAO
1
;
Yunchao HUANG
1
Author Information
1. Department of Thoracic Surgery I, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
2. Department of Nephrology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.
3. Department of Intensive Care Unit, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
- Publication Type:Journal Article
- Keywords:
Invasive adenocarcinoma;
Invasive non-mucinous adenocarcinoma;
Lung neoplasms;
Pathological subtypes
- MeSH:
Humans;
Lung Neoplasms/pathology*;
Adenocarcinoma of Lung/pathology*;
Adenocarcinoma/pathology*;
Prognosis;
Lymphatic Metastasis;
Neoplasm Staging;
Retrospective Studies
- From:
Chinese Journal of Lung Cancer
2023;26(1):22-30
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer death in the world today, and adenocarcinoma is the most common histopathological type of lung cancer. In May 2021, World Health Organization (WHO) released the 5th edition of the WHO classification of thoracic tumors, which classifies invasive non-mucinous adenocarcinoma (INMA) into lepidic adenocarcinoma, acinar adenocarcinoma, papillary adenocarcinoma, solid adenocarcinoma, and micropapillary adenocarcinoma based on its histological characteristics. These five pathological subtypes differ in clinical features, treatment and prognosis. A complete understanding of the characteristics of these subtypes is essential for the clinical diagnosis, treatment options, and prognosis predictions of patients with lung adenocarcinoma, including recurrence and progression. This article will review the grading system, morphology, imaging prediction, lymph node metastasis, surgery, chemotherapy, targeted therapy and immunotherapy of different pathological subtypes of INMA.
.
